ESC Premium Access

Estimated effect of NOACs compared to Vitamin K Antagonists in real-world atrial fibrillation patients: Data from FANTASIA Registry.


About the speaker

Doctor Maria Asuncion Esteve Pastor

Virgen de la Arrixaca University Clinical Hospital, Murcia (Spain)
0 follower

9 more presentations in this session

Performance of the HAS-BLED, ATRIA, and PRECISE-DAPT Bleeding Risk Scores in Atrial Fibrillation Patients Using Antiplatelet Agents or Oral Anticoagulants

Speaker: Mr J. Choi (Busan, KR)


Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease

Speaker: Doctor J. Strange (Copenhagen, DK)


Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly asian patients with atrial fibrillation

Speaker: Doctor T. Chao (Taipei, TW)


Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis

Speaker: Mrs A. Kang (Lawrenceville, US)


Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Speaker: Professor H. Bonnemeier (Kiel, DE)


Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

Speakers: Doctor M. Esteve Pastor, Mr J. Choi, Doctor J. Strange, Doctor T. Chao, Mrs A. Kang...

About the event



31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk